Mercy BioAnalytics: Dawn Mattoon, Paul Blavin

Mercy BioAnalytics, a Boston area company developing cancer detection test based on extracellular vesicle analyses, said that Dawn Mattoon has assumed the role of CEO and become a member of the board of directors, transitioning from her prior role as chief operating officer. Previous CEO Paul Blavin has transitioned to vice chairman of the board. Mattoon joined Mercy as COO in 2022. Over a nearly 20-year career, she has led research and development, strategy, commercialization, and general management for a broad range of companies including Quanterix, Invitrogen, Life Technologies, Thermo Fisher Scientific, and Cell Signaling Technologies. She holds a PhD in molecular genetics from Yale University, where she also completed her postdoctoral fellowship.

Blavin, Mercy's cofounder, served as its CEO from March 2020 through February 2023. Prior to Mercy, his career in finance included tenures as president of insurance holding company First Mercury Financial; cofounder of PWB Value Partners; and investment banker with Citibank and with Donaldson, Lufkin & Jenrette. He holds an MBA from Harvard Business School and a BA in accounting from the University of Michigan.